May 28, 2014

Genomics-Enabled Drug Repositioning and RepurposingInsights From an IOM Roundtable Activity

Author Affiliations
  • 1Pfizer Worldwide Research and Development, Groton, Connecticut
  • 2Institute of Medicine, Washington, DC
  • 3Duke University Institute for Genome Sciences and Policy, Durham, North Carolina

Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2014;311(20):2063-2064. doi:10.1001/jama.2014.3002

Drug repositioning or drug repurposing (terms often used interchangeably) is the process whereby alternative uses or indications are identified for a drug. Repurposing can encompass the pursuit of novel use of a drug during its normal development cycle or after a drug has been approved and marketed. More recently the term drug repositioning has been specifically applied to the use of compounds previously discontinued from development for novel indications. The increasing costs of drug development and reduced output in the pharmaceutical industry (fewer new molecules entering drug development and higher failure rates in phase 3 trials) have led to renewed interest in drug repurposing as a potentially viable strategy to speed the delivery of new medicines to patients with unaddressed needs.1

First Page Preview View Large
First page PDF preview
First page PDF preview